



**Supplementary Figure 13.** GDNF-Fc protects the sympathetic nervous system from cisplatin damage. **(a)** GDNF-Fc has biological activity: dose-response quantification of the percentage of PC12ES cells differentiated towards neurons after incubation with the indicated concentrations of GDNF-Fc for 1 week. **(b)** Experimental design to determine whether GDFN-Fc protects sympathetic fibers from cisplatin-induced damage and accelerates BM recovery after transplantation. **(c)** GDNF-Fc treatment reduced sensory neuropathy as determined by a nociception assay ( $n = 7-10$  mice per group). **(d)** Survival of mice treated as indicated in **b** ( $n = 3-15$ ). **(e-g)** Number of BMNC **(e)**, CFU-C **(f)**, and LSKF cells **(g)** per femur in mice treated as indicated in **b**, 4 weeks after transplant;  $n = 5-7$ . **(h)** Quantification of Th<sup>+</sup> fiber density in the BM of mice treated as in **b** 4 weeks after transplantation.  $n = 4-6$  per group (Left Panel). Representative immunofluorescence staining to assess Th<sup>+</sup> fibers (red) in the BM (DAPI, blue). Scale bars, 40  $\mu\text{m}$  (Right Panels) Sal, saline; G, GDNF-Fc.